Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 1;24:6085–6092. doi: 10.12659/MSM.908979

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Med Sci Monit, 2018

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

PMC Copyright notice

Changes in dysmenorrhea, hemoglobin, serum cancer antigen 125 (CA125), uterine volume, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) levels before and after implantation of the subcutaneous device containing 68 mg of etonogestrel. (A) Dysmenorrhea, before and after subcutaneous etonogestrel implantation. (B) Hemoglobin (Hb) levels (g/dL), before and after subcutaneous etonogestrel implantation. (C) Serum cancer antigen 125 (CA125) levels (U/ml), before and after subcutaneous etonogestrel implantation. (D) Uterine volume measurements (mm), before and after subcutaneous etonogestrel implantation. (E) Follicle stimulating hormone (FSH) levels (mIU/mL), before and after subcutaneous etonogestrel implantation. (F) Luteinizing hormone (LH) levels (IU/L), before and after subcutaneous etonogestrel implantation. (G) Estradiol (E2) levels (pg/mL), before and after subcutaneous etonogestrel implantation.